Amgen Inc. is a leading American biotechnology company headquartered in Thousand Oaks, California. Founded in 1980, Amgen focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics.

About Amgen, Inc.

Amgen Inc. is one of the world’s leading biotechnology companies, headquartered in Thousand Oaks, California, USA. Founded in 1980, Amgen has built its reputation by focusing on molecular biology and biochemistry to develop innovative therapies for serious illnesses.

Amgen’s core business lies in the discovery, development, manufacturing, and commercialization of human therapeutics. The company primarily addresses areas such as oncology (cancer), cardiovascular disease, bone health, nephrology (kidney disease), and inflammation. Notable Amgen products include Enbrel (for autoimmune diseases), Neulasta (to reduce infection risk in chemotherapy patients), Repatha (to lower LDL cholesterol), and Prolia (for osteoporosis).

Amgen is recognized for its pioneering work in biologic drugs, which are medications derived from living organisms, and has heavily invested in biosimilars—affordable versions of biologic treatments. The company operates globally, with research facilities, manufacturing plants, and commercial operations in North America, Europe, Asia, and Latin America.

Through continuous investment in R&D, Amgen aims to deliver breakthroughs that improve patient outcomes and reduce the societal burden of chronic disease.

Vision dan Mission Amgen, Inc. 

Vision of Amgen Inc.

“To be the world’s best human therapeutics company.”

Amgen envisions a future where biotechnology can transform the lives of patients around the globe. The company aims to harness cutting-edge science and innovation to develop medicines that significantly improve human health.

Mission of Amgen Inc.

“To serve patients.”

This simple but powerful mission reflects Amgen’s core purpose: every discovery, development, and decision is made with the goal of improving patients’ lives. The company is committed to delivering innovative therapies that address serious diseases and unmet medical needs by combining advanced science with a strong sense of responsibility.

Products of Amgen, Inc.

Amgen Inc. is a leading global biotechnology company focused on developing innovative therapies for serious illnesses. Its product portfolio spans multiple therapeutic areas, including oncology, nephrology, cardiology, inflammation, and bone health.

1. Oncology (Cancer)

• Kyprolis® (carfilzomib)
  Treatment for relapsed or refractory multiple myeloma, a type of blood cancer.
• Blincyto® (blinatumomab)
  A bispecific T-cell engager (BiTE®) immunotherapy for acute lymphoblastic leukemia (ALL).
• Imlygic® (talimogene laherparepvec)
  An oncolytic viral therapy for treating melanoma.

2. Bone Health

• Prolia® (denosumab)
  A monoclonal antibody used to treat osteoporosis in postmenopausal women and men at high risk of fracture.
• Evenity® (romosozumab-aqqg)
  Helps build bone in people with osteoporosis at high risk for fracture.

3. Cardiovascular Diseas

• Repatha® (evolocumab)
  A PCSK9 inhibitor used to lower LDL cholesterol and reduce the risk of heart attacks and strokes.

4. Nephrology (Kidney Disorders)

• Aranesp® (darbepoetin alfa)
  Treats anemia caused by chronic kidney disease and chemotherapy.
• Parsabiv® (etelcalcetide)
  Treats secondary hyperparathyroidism in patients on hemodialysis.

5. Rheumatology and Inflammation

• Enbrel® (etanercept)
  Used for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
• Otezla® (apremilast)
  An oral PDE4 inhibitor for treating plaque psoriasis and psoriatic arthritis.

6. Biosimilars

Amgen also produces biosimilar drugs that are highly similar to already approved biologics, including:

• Mvasi® (biosimilar to Avastin®)
• Kanjinti® (biosimilar to Herceptin®)
• Amgevita® (biosimilar to Humira®)

These biosimilars help improve access to critical biologic therapies at lower costs.

Key Figures at Amgen, Inc.

Amgen Inc. is led by a group of seasoned executives and board members with deep expertise in biotechnology, healthcare, finance, and innovation. Below are the key figures currently steering the company:

1. Robert A. Bradway – Chairman and Chief Executive Officer (CEO)

Joined Amgen in 2006 as VP of Operations Strategy, became CEO in 2012 and Chairman in 2013. Former Managing Director at Morgan Stanley. Under his leadership, Amgen has expanded globally and deepened its pipeline in oncology, cardiology, and biosimilars.

2.  Murdo Gordon – Executive VP, Global Commercial Operations

Joined Amgen in 2018 from Bristol Myers Squibb, and oversees worldwide commercial operations, including sales and marketing strategy.

3. Peter H. Griffith – Executive VP and Chief Financial Officer (CFO)

Responsible for Amgen’s global finance operations, and former CFO of Sherwood Canyon Group, LLC and had a long tenure at EY.

4. David M. Reese, M.D. – Executive VP, Research and Development

Leads Amgen’s R&D division, and drives clinical development, regulatory, medical affairs, and global patient safety.

5. Esteban Santos, Ph.D. – Executive VP, Operations

Oversees manufacturing, quality, and supply chain, and ensures the global production of biologic and biosimilar medicines.

6. Lori Johnston – Executive VP, Human Resources

Leads talent acquisition, people development, and diversity programs globally.

7. Cynthia M. Patton – Senior VP, Chief Compliance Officer

Heads global compliance and business ethics programs.

Stock Price Amgen, Inc.

• Current Price: $270.45 USD
• Daily Change: −1.57%
• 52-Week Range: $253.30 – $346.85
• Market Capitalization: Approximately $145.42 billion
• Price-to-Earnings (P/E) Ratio: 35.82
• Beta: 0.51 (indicating lower volatility compared to the market average)
• Dividend Yield: 3.52%
• Recent Earnings (Q1 2025): Earnings per share (EPS) of $4.90, surpassing the consensus estimate of $4.18. Revenue reached $8.15 billion, marking a 9.4% increase year-over-year. 

Amgen’s stock has experienced fluctuations over the past year, with a notable high of $346.85 and a low of $253.30. The company’s consistent dividend payouts and strong financial performance continue to attract investor interest.

History and Evolution of Amgen, Inc.

• Founding and Early Years (1980s)
  Amgen Inc., short for Applied Molecular Genetics, was founded in 1980 in Thousand Oaks, California. It was established during the early wave of biotechnology innovation with a focus on genetically engineered human therapeutics. Its mission: to unlock the potential of biology for patients suffering from serious illnesses.

In 1989, Amgen achieved a major milestone with the FDA approval of Epogen® (epoetin alfa), a synthetic version of erythropoietin used to treat anemia in patients undergoing kidney dialysis. It was one of the first blockbuster biotech drugs and a catalyst for Amgen’s rapid growth.

• 1990s: Expansion and Globalization
  Throughout the 1990s, Amgen solidified its position as a biotechnology leader. The company introduced Neupogen® (filgrastim) in 1991 to reduce infection risk in cancer patients receiving chemotherapy. 

By the end of the decade, Amgen had expanded its manufacturing capacity globally and was listed among the top biotech companies worldwide.

• 2000s: Diversification and Acquisitions
  Amgen diversified its portfolio with the launch of Aranesp®, an improved version of Epogen, and Enbrel®, a treatment for autoimmune diseases, after acquiring Immunex Corporation in 2002 for $16 billion. This acquisition marked a turning point, helping Amgen become a major player in immunology.

Amgen also invested heavily in R&D, opening research facilities in the U.S. and abroad, including partnerships with academic institutions.

• 2010s: Biosimilars and Strategic Shifts
  Amgen embraced biosimilars, launching several to compete in the rising market of off-patent biologics, such as Mvasi® (biosimilar to Avastin) and Kanjinti® (biosimilar to Herceptin). The company also focused on expanding into cardiovascular and oncology sectors with drugs like Repatha® (evolocumab) and Blincyto® (blinatumomab).

During this time, Amgen advanced its digital transformation and began leveraging artificial intelligence and big data for clinical development and manufacturing optimization.

• 2020s–Present: Innovation and Global Leadership
  Amgen continues to evolve with a focus on oncology, cardiovascular, and inflammatory diseases. In 2022, it acquired ChemoCentryx to strengthen its inflammation pipeline, and in 2023, completed the $28 billion acquisition of Horizon Therapeutics, expanding its presence in rare diseases.

Today, Amgen is one of the largest biotechnology firms in the world, with operations in over 100 countries, a robust pipeline, and a mission to serve patients through science-driven innovation.

How to Buy Amgen, Inc. (AMGN) Stocks

Interested in buying shares of this tech company? You can buy Amgen, Inc. (AMGN) shares with simple steps:

1. Install Nanovest app on the App Store or Play Store.
2. Register according to the instructions.
3. Verify your identity for security and convenience when buying stocks through the KYC feature which you can do in just 1 minute.
4. Top Up your balance to your Nanovest account.
5. Go to the stock menu, search and select Amgen, Inc. (AMGN).
6. Click the Buy button and confirm the purchase with your desired amount. You can start with only IDR 5,000.

Before investing in the stocks you want, do some research and analysis first. You can do this by checking company profile, industry conditions, company financial reports, and analyzing previous stock price movements. This analysis is important so that you can develop an accurate investment strategy and minimize losses.

Is It Safe to Buy Amgen, Inc. (AMGN) Stock on Nanovest?

Of course. Nanovest is supported by a number of professional partners who have a good reputation in providing their services. One of them is supported by S-Quantum Engine technology by Sinarmas Financial Services.

For global and US stocks, Nanovest partners with brokers registered with the United Stated Financial Industry Regulatory Authority (FINRA) – which insures brokerage accounts held by Nanovest users up to U$S 500k by the United States Securities Investor Protection Corporation (SIPC).

For crypto assets, Nanovest is registered with the Commodity Futures Trading Supervisory Agency (Bappebti). The Nanovest platform itself has also been insured through a partnership with Sinarmas Insurance.

Disclaimer

All content on this website is for informational purposes and doesn’t constitute a recommendation to buy/sell any stock or digital asset. Investors should understand the nature of stocks and digital assets, including return and risk requirements of the assets. We encourage investors to fully understand the assets and risks before making any investment. Always do your own research.

See More Stocks

• Netflix, Inc. (NFLX) Stocks
• Meta Platforms, Inc. (META) Stocks
• Alphabet Inc. Class C (GOOG) Stocks
• Spotify Technology SA (SPOT) Stocks
• Amazon.com, Inc. (AMZN) Stocks
• Intel Corporation (INTC) Stocks
• Apple Inc. (AAPL) Stocks
• Microsoft Corporation (MSFT) Stocks
• Tesla, Inc. (TSLA) Stocks
• Alibaba Group (BABA) Stocks
• Visa Inc. (V) Stocks
• Citigroup Inc. (C) Stocks
• JPMorgan Chase & Co (JPM) Stocks
• HSBC Holdings plc (HSBC) Stocks
• Chevron Corporation (CVX) Stocks
• General Motors Co (GM) Stocks